Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

iSpecimen (ISPC) EBT Margin (2020 - 2025)

Historic EBT Margin for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to 2654.92%.

  • iSpecimen's EBT Margin fell 25906200.0% to 2654.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 366.36%, marking a year-over-year decrease of 2730900.0%. This contributed to the annual value of 138.39% for FY2024, which is 291500.0% down from last year.
  • Latest data reveals that iSpecimen reported EBT Margin of 2654.92% as of Q3 2025, which was down 25906200.0% from 255.36% recorded in Q2 2025.
  • iSpecimen's EBT Margin's 5-year high stood at 48.04% during Q2 2021, with a 5-year trough of 2654.92% in Q3 2025.
  • Moreover, its 5-year median value for EBT Margin was 94.64% (2022), whereas its average is 256.2%.
  • In the last 5 years, iSpecimen's EBT Margin soared by 1365400bps in 2024 and then tumbled by -25906200bps in 2025.
  • iSpecimen's EBT Margin (Quarter) stood at 79.54% in 2021, then rose by 8bps to 72.92% in 2022, then crashed by -51bps to 109.83% in 2023, then plummeted by -270bps to 406.28% in 2024, then tumbled by -553bps to 2654.92% in 2025.
  • Its EBT Margin stands at 2654.92% for Q3 2025, versus 255.36% for Q2 2025 and 154.85% for Q1 2025.